CogState (CGS.AX) Aktie Kurs
CogState Kurs
De seneste 19 år voksede CogStates omsætning med 20,0 % årligt og nåede 53,09 Mio. USD. Indtjening pr. aktie er vokset med 8,5 % om året de seneste 16 år. For CogState er nettoavance på 19,1 % op i forhold til 16,0 % for et par år siden. Ved dagens kurs bliver direkteafkastet cirka 1,21 %. Udlodningsandelen er omkring 34 % af indtjeningen. Konsensus 12-måneders kursmål for CogState er 2,15 USD, cirka under kursen med 8,8 %. Af 6 analytikere anbefaler 5 køb — den samlede vurdering er Køb.
CogState aktiekurs
CogState aktie og aktieanalyse
Hyppigt stillede spørgsmål om CogState-aktien
CogState Ltd is a leading provider of cognitive testing services for clinical trials, academic research, and healthcare. The company's business model revolves around using their digital tools and technologies to measure and enhance cognitive function in patients. By collaborating with pharmaceutical companies, academic institutions, and healthcare organizations, CogState Ltd aims to improve patient outcomes and accelerate the development of new treatments. With their expertise and extensive database, CogState Ltd offers customized solutions and prognostic insights to address the cognitive challenges faced in various industries.
CogState Ltd is primarily active in the healthcare and pharmaceutical industries.
The main competitors of CogState Ltd in the market are Cambridge Cognition Holdings PLC, Neurotrack Technologies Inc., and CogniFit Ltd. These companies also specialize in cognitive assessment and provide similar solutions and services. However, CogState Ltd distinguishes itself through its innovative technologies and partnerships, including collaborations with leading pharmaceutical companies. With its strong focus on enhancing the understanding and measurement of cognitive function, CogState Ltd continues to remain competitive in the market and deliver valuable solutions to its clients.
CogState Ltd is a renowned company with a rich history and background. Founded in 1999, CogState specializes in cognitive testing and offers innovative solutions to improve brain health assessment. With its headquarters in Melbourne, Australia, the company has expanded its global presence, serving various sectors including pharmaceuticals, biotechnology, and academic research. CogState has developed cutting-edge technologies and software platforms to deliver accurate and efficient cognitive assessments, benefiting patients, researchers, and professionals worldwide. Known for its advanced cognitive testing methods and commitment to enhancing brain health, CogState Ltd has established itself as a trusted industry leader.
CogState Ltd has achieved several significant milestones in its history. One key achievement is the development and commercialization of its pioneering cognitive testing technology, known as the CogState Computerized Cognitive Assessment Tool (CCAT). This innovative tool is widely utilized in clinical trials and research studies worldwide, enabling precise and objective measurement of cognitive function. Additionally, CogState Ltd has successfully established strategic partnerships with leading pharmaceutical companies, academic institutions, and healthcare providers, facilitating the widespread adoption of its solutions. The company continues to thrive through ongoing research and development, further cementing its position as a global leader in cognitive assessment technology.
CogState Ltd is primarily present in Australia, the United States, and Europe.
CogState Ltd represents a set of core values and a corporate philosophy that drive its operations. The company is committed to innovation, delivering cutting-edge solutions in the fields of cognitive assessment and clinical trials. CogState prioritizes integrity, ensuring transparent and ethical practices in all aspects of its business. With a focus on collaboration, CogState fosters strong partnerships to drive mutual success. The company values dedication to excellence, constantly striving for improvement and delivering high-quality products and services. CogState fosters a customer-centric approach, prioritizing customer satisfaction and delivering tailored solutions. Overall, CogState Ltd embodies a commitment to innovation, integrity, collaboration, excellence, and customer-centricity in its corporate philosophy.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 2,15 USD for CogState-aktien (median: 2,15 USD), svarende til -8,8 % i forhold til seneste kurs. Konsensus bygger på 6 analytikervurderinger.
7 analytikere vurderer i øjeblikket CogState-aktien: 6 anbefaler køb, 1 hold og 0 salg. For 2026 forventer analytikere, at CogState genererer omsætning på 128,65 Mio. USD og indtjening pr. aktie på 0,09 USD.
Omregnet til den aktuelle valutakurs handles CogState-aktien til 2,11 EUR (2,36 USD).
CogState-aktien (CGS.AX) er noteret på 2 børser, herunder: ASX (CGS.AX).
CogState Ltd is an innovative company specializing in the development and marketing of cognitive testing solutions. The company offers a wide range of products and services that can be used in the fields of pharmaceutical research, clinical diagnostics, and sports performance optimization. The three main business divisions of CogState Ltd include research and development of cognitive tests, clinical diagnostics and monitoring of patients with neurodegenerative disorders, and solutions for improving sports performance. The company's products are rooted in today's technology, as they are exclusively offered online. They allow for remote diagnosis and supervision of patients, saving time for therapists and improving diagnostic accuracy. The company's proprietary software platform enables researchers to effectively manage their studies and present study results in a concise format. CogState Ltd has a strategy in place to continue offering unique and expanding product offerings, allowing the company to remain a strong competitor in the industry.
forventet-omsætningen for CogState er 128,65 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for CogState er 16,22 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for CogState er i øjeblikket 25,31. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af CogState-aktien.
Pris-til-salgs-forholdet (P/S) for CogState er i øjeblikket 3,19. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for CogState-aktien.
AlleAktien-kvalitetsscore for CogState er 6/10.
ISIN for CogState er AU000000CGS8. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
Tickeren for CogState er CGS.AX. Tickersymbolet bruges til at handle CogState-aktier på børsen.
CogState aktie
CogState Peer Group
CogState Ticker
CogState FIGI
Alle fundamentale data om CogState i deep dive
Vores aktieanalyse af CogState-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos CogState. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: